Methadone in THA for Post-op Pain and Opioid Reduction

Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-75
SponsorMedical University of South Carolina

About this trial

This randomized, double-blind controlled trial investigates whether intraoperative intravenous methadone (0.15 mg/kg based on ideal body weight) reduces acute postoperative pain and opioid consumption in patients undergoing elective total hip arthroplasty under spinal anesthesia with mepivacaine. The primary outcome is patient-reported pain on a visual analog scale (VAS) 30-60 minutes after arrival in the post-anesthesia care unit (PACU). Secondary outcomes include opioid use, pain scores over time, incidence of nausea/vomiting, and quality of recovery. A total of 162 subjects will be enrolled at MUSC surgical sites.

Eligibility criteria

Qualifiers

Ages 18-75 years of age

Undergoing elective primary total hip arthroplasty with mepivacaine in the spinal anesthesia

Allergy to methadone or mepivacaine

Severe liver disease defined as Child's Pugh Class C

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Methadone

Treatment groups

162 Participants
are divided into 2 treatment groups